Parke-Davis' HMG-CoA reductase inhibitor atorvastatin has outperformed other statin drugs in head-to-head comparative studies, according to company chairman Ronald Cresswell at an analysts' briefing in New York, USA.
Atorvastatin, at a dose of 10mg, is more effective in reducing serum lipids than all the other available statins at their highest approved doses, said Dr Cresswell. The drug lowers low-density lipoprotein cholesterol by as much as 60%, triglycerides by as much as 40%, and raises beneficial high-density lipoprotein cholesterol by around 12%.
Dr Cresswell predicted that a New Drug Application for atorvastatin would be filed in the middle of next year, and the company hopes to achieve sales of $800 million a year at peak. The company expects to build on the lipid-lowering franchise it has achieved with its Lopid (gemfibrozil) range of products.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze